Englander Institute for Precision Medicine

Pan-cancer proteogenomics connects oncogenic drivers to functional states.

TitlePan-cancer proteogenomics connects oncogenic drivers to functional states.
Publication TypeJournal Article
Year of Publication2023
AuthorsLi Y, Porta-Pardo E, Tokheim C, Bailey MH, Yaron TM, Stathias V, Geffen Y, Imbach KJ, Cao S, Anand S, Akiyama Y, Liu W, Wyczalkowski MA, Song Y, Storrs EP, Wendl MC, Zhang W, Sibai M, Ruiz-Serra V, Liang W-W, Terekhanova NV, Rodrigues FMartins, Clauser KR, Heiman DI, Zhang Q, Aguet F, Calinawan AP, Dhanasekaran SM, Birger C, Satpathy S, Zhou DCui, Wang L-B, Baral J, Johnson JL, Huntsman EM, Pugliese P, Colaprico A, Iavarone A, Chheda MG, Ricketts CJ, Fenyö D, Payne SH, Rodriguez H, Robles AI, Gillette MA, Kumar-Sinha C, Lazar AJ, Cantley LC, Getz G, Ding L
Corporate AuthorsClinical Proteomic Tumor Analysis Consortium
JournalCell
Volume186
Issue18
Pagination3921-3944.e25
Date Published2023 Aug 31
ISSN1097-4172
KeywordsCell Transformation, Neoplastic, DNA Copy Number Variations, Humans, Neoplasms, Oncogenes, Proteogenomics
Abstract

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-cancer analysis uncovers insights into the impacts of cancer drivers by identifying their significant cis-effects and distal trans-effects quantified at the RNA, protein, and phosphoprotein levels. Salient observations include the association of point mutations and copy-number alterations with the rewiring of protein interaction networks, and notably, most cancer genes converge toward similar molecular states denoted by sequence-based kinase activity profiles. A correlation between predicted neoantigen burden and measured T cell infiltration suggests potential vulnerabilities for immunotherapies. Patterns of cancer hallmarks vary by polygenic protein abundance ranging from uniform to heterogeneous. Overall, our work demonstrates the value of comprehensive proteogenomics in understanding the functional states of oncogenic drivers and their links to cancer development, surpassing the limitations of studying individual cancer types.

DOI10.1016/j.cell.2023.07.014
Alternate JournalCell
PubMed ID37582357
Grant ListR33 CA263705 / CA / NCI NIH HHS / United States
U01 CA214116 / CA / NCI NIH HHS / United States
U24 CA210979 / CA / NCI NIH HHS / United States
U24 CA210972 / CA / NCI NIH HHS / United States
U24 CA210954 / CA / NCI NIH HHS / United States
U24 CA271012 / CA / NCI NIH HHS / United States
U24 CA210986 / CA / NCI NIH HHS / United States
U01 CA214125 / CA / NCI NIH HHS / United States
U01 CA214114 / CA / NCI NIH HHS / United States
U24 CA210993 / CA / NCI NIH HHS / United States
U24 CA210985 / CA / NCI NIH HHS / United States
U24 CA270823 / CA / NCI NIH HHS / United States
U24 CA210955 / CA / NCI NIH HHS / United States
U24 CA210967 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021